Galectin Therapeutics Inc.
GALT US3632252025
🆔
Registration No.
NV20011197078
💰
Capitalization
Small-cap
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
🔗
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7% | -51% | 41% | -26% | -1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
📊
Transactions
30
🙍
Insiders
8
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Callicutt Jack W CFO |
6.44 USD |
8,706 Sold |
56,054 USD |
12/09/2025 | 12/09/2025 |
| Lewis Joel CEO |
6.36 USD |
14,000 Sold |
89,048 USD |
12/09/2025 | 12/09/2025 |
| Eldred Kary |
2.93 USD |
1,000 Bought |
2,925 USD |
21/07/2025 | 21/07/2025 |
| Eldred Kary |
2.93 USD |
1,000 Bought |
2,925 USD |
21/07/2025 | 21/07/2025 |
| Freeman Kevin D |
2.90 USD |
5,000 Bought |
14,495 USD |
17/07/2025 | 17/07/2025 |
| Shlevin Harold H. |
1.16 USD |
6,500 Bought |
7,540 USD |
30/12/2024 | 30/12/2024 |
| Freeman Kevin D |
0.81 USD |
10,000 Bought |
8,134 USD |
24/12/2024 | 24/12/2024 |
| Eldred Kary |
0.82 USD |
13,469 Bought |
11,045 USD |
24/12/2024 | 24/12/2024 |
| Zordani Richard A. Jr. |
0.82 USD |
10,000 Bought |
8,164 USD |
24/12/2024 | 24/12/2024 |
| Lewis Joel CEO |
0.89 USD |
56,000 Sold |
49,610 USD |
23/12/2024 | 23/12/2024 |